189 related articles for article (PubMed ID: 24412823)
1. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).
Luminari S; Biasoli I; Versari A; Rattotti S; Bottelli C; Rusconi C; Merli F; Spina M; Ferreri AJ; Zinzani PL; Gallamini A; Franceschetto A; Boccomini C; Franceschetti S; Salvi F; Raimondo FD; Carella AM; Micol Q; Balzarotti M; Musto P; Federico M
Ann Oncol; 2014 Feb; 25(2):442-7. PubMed ID: 24412823
[TBL] [Abstract][Full Text] [Related]
2. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi.
Luminari S; Biasoli I; Arcaini L; Versari A; Rusconi C; Merli F; Spina M; Ferreri AJ; Zinzani PL; Gallamini A; Mastronardi S; Boccomini C; Gaidano G; D'Arco AM; Di Raimondo F; Carella AM; Santoro A; Musto P; Federico M
Ann Oncol; 2013 Aug; 24(8):2108-12. PubMed ID: 23585513
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV
Annunziata S; Cuccaro A; Tisi MC; Hohaus S; Rufini V
Ann Nucl Med; 2018 Jun; 32(5):372-377. PubMed ID: 29464479
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
Trotman J; Fournier M; Lamy T; Seymour JF; Sonet A; Janikova A; Shpilberg O; Gyan E; Tilly H; Estell J; Forsyth C; Decaudin D; Fabiani B; Gabarre J; Salles B; Van Den Neste E; Canioni D; Garin E; Fulham M; Vander Borght T; Salles G
J Clin Oncol; 2011 Aug; 29(23):3194-200. PubMed ID: 21747087
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
Luminari S; Galimberti S; Versari A; Biasoli I; Anastasia A; Rusconi C; Ferrari A; Petrini M; Manni M; Federico M
Haematologica; 2016 Feb; 101(2):e66-8. PubMed ID: 26471485
[No Abstract] [Full Text] [Related]
6. The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma.
Lu Z; Lin M; Downe P; Chong S; Ling S
Ann Nucl Med; 2014 Oct; 28(8):805-11. PubMed ID: 25008291
[TBL] [Abstract][Full Text] [Related]
7. End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis.
Pyo J; Won Kim K; Jacene HA; Sakellis CG; Brown JR; Van den Abbeele AD
Clin Cancer Res; 2013 Dec; 19(23):6566-77. PubMed ID: 24052020
[TBL] [Abstract][Full Text] [Related]
8. FDG PET/CT predictive role in follicular lymphoma.
Lopci E; Zanoni L; Chiti A; Fonti C; Santi I; Zinzani PL; Fanti S
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):864-71. PubMed ID: 22354449
[TBL] [Abstract][Full Text] [Related]
9. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.
Wong-Sefidan I; Byrtek M; Zhou X; Friedberg JW; Flowers CR; Zelenetz AD; Dawson KL; Reid E
Leuk Lymphoma; 2017 Apr; 58(4):809-815. PubMed ID: 27562750
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.
Trotman J; Luminari S; Boussetta S; Versari A; Dupuis J; Tychyj C; Marcheselli L; Berriolo-Riedinger A; Franceschetto A; Julian A; Ricard F; Guerra L; Haioun C; Biasoli I; Tilly H; Federico M; Salles G; Meignan M
Lancet Haematol; 2014 Oct; 1(1):e17-27. PubMed ID: 27030064
[TBL] [Abstract][Full Text] [Related]
11. Basal (18)F-FDG PET/CT in follicular lymphoma: A comparison of metabolic and clinical variables in the prognostic assessment.
Jiménez Londoño GA; García Vicente AM; Poblete García VM; Amo-Salas M; Calle Primo C; Ibañez García Á; Martínez Sanchís B; López-Fidalgo JF; Solano Ramos F; Martínez Hellín A; Díaz Morfa M; Soriano Castrejón Á
Rev Esp Med Nucl Imagen Mol; 2016; 35(5):298-305. PubMed ID: 27312693
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
13. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review.
Adams HJA; Nievelstein RAJ; Kwee TC
Ann Hematol; 2016 Jan; 95(1):11-18. PubMed ID: 26576560
[TBL] [Abstract][Full Text] [Related]
15. End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
Dixon JG; Dimier N; Nielsen T; Zheng J; Marcus R; Morschhauser F; Evens AM; Federico M; Blum KA; Shi Q
Br J Haematol; 2022 Jul; 198(2):333-337. PubMed ID: 35491747
[TBL] [Abstract][Full Text] [Related]
16. End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.
Kato K; Izutsu K; Nishikori M; Shibayama H; Maeda Y; Yoshimura K; Tateishi U; Miyamoto T; Matsuda Y; Ishikawa J; Rai S; Takahashi T; Yamauchi T; Matsumura I; Akashi K; Kanakura Y; Suzumiya J
Int J Hematol; 2024 Jun; 119(6):677-685. PubMed ID: 38519820
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
18. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.
Dupuis J; Berriolo-Riedinger A; Julian A; Brice P; Tychyj-Pinel C; Tilly H; Mounier N; Gallamini A; Feugier P; Soubeyran P; Colombat P; Laurent G; Berenger N; Casasnovas RO; Vera P; Paone G; Xerri L; Salles G; Haioun C; Meignan M
J Clin Oncol; 2012 Dec; 30(35):4317-22. PubMed ID: 23109699
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.
Lopci E; Santi I; Derenzini E; Fonti C; Savelli G; Bertagna F; Bellò M; Botto B; Huglo D; Morschhauser F; Zinzani P; Fanti S
Ann Oncol; 2010 Sep; 21(9):1877-1883. PubMed ID: 20147744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
